Now showing 1 - 2 of 2
ItemLicensing regulators Geminin and Cdt1 identify progenitor cells of the mouse CNS in a specific phase of the cell cycleSpella, M ; Britz, O ; Kotantaki, P ; Lygerou, Z ; Nishitani, H ; Ramsay, RG ; Flordellis, C ; Guillemot, F ; Mantamadiotis, T ; Taraviras, S (Elsevier BV, 2007-06)
ItemBACE inhibitors as potential therapeutics for Alzheimer's disease.Evin, G ; Kenche, VB (Bentham Science Publishers Ltd., 2007-11)Accumulation of Abeta peptide in the brain results in the formation of amyloid plaques characteristic of Alzheimer's disease (AD) pathology. Abeta soluble oligomers and protofibrils are neurotoxic and these are believed to be a major cause of neurodegeneration in AD. Abeta is derived from a precursor protein by two sequential cleavage steps involving beta- and gamma-secretases, two proteolytic enzymes that represent rational drug targets. beta-secretase was identified as the membrane-anchored aspartyl protease BACE (or BACE1) and found to be elevated in brain cortex of patients with sporadic Alzheimer's disease. In this review, we summarize current approaches towards the development of BACE inhibitors with focus on bioactive compounds and related patents. Recent reports have described drugs that are effective at inhibiting Abeta production in the brain of transgenic mouse models. The beginning of Phase I clinical trials has been approved for one of them and we can expect that in the near future BACE inhibitors will provide novel effective therapeutics to treat AD.